The purpose of this legislation, known as the Protecting Equal Access to Thyroid Act of 2026, is to clarify how certain biologic products are classified under U.S. law. Specifically, it aims to ensure that a biologic product cannot be labeled as a biological product simply because it contains a protein that does not have any clinical effect. The key provision of this act amends an existing section of the Public Health Service Act. It states that a biologic cannot be considered a biological product solely due to the presence of a clinically inactive protein.